Giant Biogene Holding Co., Ltd.

2367

KYG3887G1091

Personal Products

Delayed Hong Kong S.E. Other stock markets 11:59:40 08/07/2025 HKT			5-day change	1st Jan Change
58.40 ^HKD	-0.17%		+5.32%	+17.03%

06-27	Giant Biogene's Controlling Shareholder Boosts Ownership; Shares Up 5%	MT
06-26	Giant Biogene's Controlling Shareholder Raises Stake; Shares Gain 1%	MT

Giant Biogene Holding Co., Ltd. Approves Special Dividend for the Year Ended 31 December 2024, Payable on or Around August 29, 2025

Published on 13/06/2025 at 23:37

Giant Biogene Holding Co., Ltd. in its AGM held on June 13, 2025 approved To declare and distribute a special dividend of RMB 0.5921 per ordinary share for the year ended 31 December 2024 to the shareholders of the Company on or around 29 August 2025 to the Shareholders whose names appear on the register of members of the Company on 24 June 2025.

Latest news about Giant Biogene Holding Co., Ltd.

Giant Biogene's Controlling Shareholder Boosts Ownership; Shares Up 5%	06-27	MT
Giant Biogene's Controlling Shareholder Raises Stake; Shares Gain 1%	06-26	MT
Giant Biogene's Controlling Shareholder to Boost Shareholding	06-10	MT
Giant Biogene Says Juzi Holding Intends To Increase Shareholding In Co With Amount No Less Than Hk$200 Million	06-09	RE
DoorDash acquires Deliveroo for $3.9bn	05-06
Giant Biogene Seeks HK$2.3 Billion in Top-Up Placement	04-17	MT
China's Giant Biogene raises about $301 million in Hong Kong share sale, term sheet shows	04-17	RE
China's Giant Biogene raises about $301 million in Hong Kong share sale, term sheet shows	04-17	RE
Giant Biogene To Raise About $250 Mln In Top Up Placement, Term Sheet Shows	04-16	RE
Jefferies Adjusts Giant Biogene Holding's Price Target to HK$91 From HK$80, Keeps at Buy	03-31	MT
Giant Biogene Holding Posts FY Gross Profit RMB 4,546.9 Million	03-26	RE
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-26	CI
Giant Biogene Holding Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong, Effective 10 January 2025	01-09	CI
Giant Biogene Holding: Strong growth momentum continues in H1	12-20
New purchases in MarketScreener's Asia portfolio	22/10/24
Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-AUG-2024.	23/08/24	CI
Giant Biogene Holding Records 47% Higher Profit in H1	19/08/24	MT
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	19/08/24	CI
Giant Biogene Launches New Brand Vpro Featuring Vlock 4D Recombinant Collagen for Cellular Anti-Aging	04/07/24	CI
Giant Biogene Places 33.2 Million Shares for About HK$1.63	27/05/24	MT
Giant Biogene’s Profit Up 47% in 2023	30/04/24	MT
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03/24	CI
Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-NOV-2023.	03/11/23	CI
Giant Biogene Holding Co., Ltd. Announces Executive Changes	03/10/23	CI
Giant Biogene Holding Co., Ltd.(SEHK:2367) added to FTSE All-World Index	18/09/23	CI

Chart Giant Biogene Holding Co., Ltd.

Duration

Period

2367: Dynamic Chart

Company Profile

Giant Biogene Holding Co Ltd is a China-based investment holding company. The Company is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The Company's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The Company also develops and manufactures rare ginsenosides technology-based functional foods. The Company mainly conducts its businesses within the domestic market.

Employees

1,758

Sector

Personal Products

Calendar

09-01 - Q2 2025 Earnings Release (Projected)

More about the company